Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention

Research output: Contribution to journalArticleAcademicpeer-review

64 Citations (Scopus)


Gastric cancer is the second leading cause of cancer-related death worldwide. A meta-analysis of seven randomized controlled trials concluded that Helicobacter pylori eradication reduces gastric cancer incidence by 35%. Current consensus is that H. pylori screening and treatment is cost-effective only in high-risk populations. This paper provides an up-to-date overview of the evidence for cost-effectiveness of H. pylori screening and treatment in different population settings and risk levels for H. pylori infection. Ten unique cost-effectiveness or cost-utility analyses were identified. All found that screening for H. pylori to prevent gastric cancer in the general population costs less than $50,000 per LYG. This finding was robust for differences in H. pylori prevalence, gender and ethnicity. Based on limited evidence, re-treatment (for treatment failure), repeated screening, limiting screening and treatment to those with the CagA phenotype, or universal treatment, does not appear to be cost-effective. However, most included studies failed to consider both the broader benefits as well as the adverse effects of widespread use of antibiotics for H. pylori. (C) 2013 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)933-947
Number of pages15
JournalBest Practice & Research in Clinical Gastroenterology
Issue number6
Publication statusPublished - 2013

Research programs

  • EMC NIHES-02-65-01

Cite this